SAT438 Nivolumab Induced Endocrinopathies- Outcomes And Learning

Disclosure: K. Kethireddi: None. S. Jhetam: None. S.B. Parthasarathy: None. Background: Nivolumab is an anti PD-1 mAB (Programmed Cell Death protein) used in the treatment of melanoma, renal, head & neck and other cancers. Use of Nivolumab either as a single therapy or in combination with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Kethireddi, Keerthi Madhurya, Jhetam, Suhail, Parthasarathy, Sathish Babu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Endocrine Disrupting Chemicals
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555001/
http://dx.doi.org/10.1210/jendso/bvad114.1068

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555001/
http://dx.doi.org/10.1210/jendso/bvad114.1068

Ejemplares similares